{
    "organizations": [],
    "uuid": "a1a89e43864cc92253e03745a01b447317c14931",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aclaris-therapeutics-a-101-45-topi/brief-aclaris-therapeutics-a-101-45-topical-solution-meets-primary-all-secondary-endpoints-in-two-phase-2-clinical-trials-for-common-warts-idUSASB0C012",
    "ord_in_thread": 0,
    "title": "BRIEF-Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Aclaris Therapeutics Inc:\n* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS\n* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS\n* ACLARIS THERAPEUTICS - ‍POSITIVE RESULTS FROM 2 PHASE 2 CLINICAL TRIALS,WART-202,WART-203 OF A-101 45% TOPICAL SOLUTION,FOR TREATMENT OF COMMON WARTS​\n* ACLARIS - ‍A-101 45% MET ALL PRIMARY,SECONDARY ENDPOINTS OF EACH TRIAL, ACHIEVING CLINICALLY,STATISTICALLY SIGNIFICANT CLEARANCE OF COMMON WARTS​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T20:06:00.000+02:00",
    "crawled": "2018-01-09T17:17:58.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "aclaris",
        "therapeutic",
        "inc",
        "aclaris",
        "therapeutic",
        "topical",
        "solution",
        "meet",
        "primary",
        "secondary",
        "endpoint",
        "two",
        "phase",
        "clinical",
        "trial",
        "common",
        "wart",
        "aclaris",
        "therapeutic",
        "topical",
        "solution",
        "meet",
        "primary",
        "secondary",
        "endpoint",
        "two",
        "phase",
        "clinical",
        "trial",
        "common",
        "wart",
        "aclaris",
        "therapeutic",
        "result",
        "phase",
        "clinical",
        "trial",
        "topical",
        "solution",
        "treatment",
        "common",
        "aclaris",
        "met",
        "primary",
        "secondary",
        "endpoint",
        "trial",
        "achieving",
        "clinically",
        "statistically",
        "significant",
        "clearance",
        "common",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}